Mda mb 231 htb 26

The human triple-negative breast cancer (TNBC) cell line MDA-MB-231 (HTB-26) was purchased from ATCC (Manassas, VA, USA) and were maintained in DMEM supplemented with 10% fetal bovine serum (Invitrogen, Paisley, UK), 200 mM L-glutamine (Invitrogen) and antibiotic-antimycotic liquid (Invitrogen) at 37 °C in a 5% CO2 humidified atmosphere.

Human breast cancer epithelial cell lines MDA-MB-231 (HTB26) and MCF-7 (HTB-22) were purchased from ATCC, USA, and KAIMRC1 cells were established in our laboratory. All the cells were maintained in advanced Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 50 units/mL penicillin and 50 μg/mL streptomycin (Gibco), and 2 mM L-glutamine (Gibco). Cells were cultured at 37 °C in a humidified 5% CO₂ atmosphere.

The breast cancer cell line MDA-MB-231 (HTB-26™), purchased from ATCC®, was cultured at 37 °C and 5% CO₂ in Dulbecco’s modified Eagle’s medium with high glucose (DMEM) (Euroclone S.p.A., Pero, Milano, Italy) supplemented with 10% heat-inactivated fetal bovine serum (FBS,) (Lonza, Verviers, Belgium), 1 mM Sodium Pyruvate (Euroclone), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco, Invitrogen Corp., Carlsbad, CA, USA). Murine macrophage Raw264.7 cells were purchased from ATCC® and cultured at 37 °C and 5% CO₂in DMEM supplemented with 10% FBS, 2 mM glutamine and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin).

The human TNBC cell lines MDA-MB-468 (HTB-132) and MDA-MB-231 (HTB-26) were obtained from ATCC (Manassas, VA, USA) and cultured in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin/streptomycin (15140-122; Gibco, Grand Island, NY, USA) at 37 °C and in 5% CO₂. HEK293FT cells used for lentivirus production were grown and maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA). Cisplatin was purchased from Sigma-Aldrich (C2210000; St. Louis, MO, USA), and the YAP inhibitors (sitravatinib: S8573; crizotinib: S1068; verteporfin: S1786; CA3: S8661) were purchased from Selleckchem (Houston, TX, USA).

Primary human breast epithelial HMEC cells (CC-2551, Lonza, Basel, Switzerland) and immortalized breast epithelial 184A1 cells (a kind gift from A/Prof. Darren Shafren, the University of Newcastle) were cultured in mammary epithelial basal medium (MEBM) supplemented with bovine pituitary extract (BPE) (0.4%), human epidermal growth factor (hEGF) (0.1%), hydrocortisone (0.1%), GA-1000 (0.1%), and insulin (0.1%) (Lonza). MCF7 (HTB-22, American Type Culture Collection (ATCC), Manassas VA, USA), T-47D (HTB-133, ATCC), MDA-MB-231 (HTB-26, ATCC), and SKBR3 (HTB-30, ATCC; a kind gift from A/Prof. Darren Shafren, the University of Newcastle) breast cancer cell lines were cultured in RPMI-1640 (GE Healthcare, Chicago, IL, USA) supplemented with 10% FBS (Sigma–Aldrich, St. Louis, MO, USA) and 2 mM L-glutamine (GE Healthcare). All cells were maintained at 37 °C with 5% CO₂ and used within four years of purchase from ATCC or Lonza, or authenticated using the GenePrint 10 System (Promega, Madison, WI, USA) as per the manufacturer’s instructions, and DNA fragments were detected by the Australian Genome Research Facility (AGRF) (Melbourne, VIC, Australia).